TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to reverse biological aging and ...

The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not ...

The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years.

Telomir-1 improved survival in progeria cells and normalized ROS levels under oxidative stress. The candidate reduced mitochondrial calcium overload, restoring cell energy balance. From tariffs to ...

As with other conditions, Telomir-1 treats the underlying causes of progeria by regulating metal ions, reducing oxidative stress, restore mitochondrial function, extending telomere length ...